TSBP1-AS1 |
|
TSBP1 and BTNL2 antisense RNA 1
|
|
|
0.638 |
0.692 |
TSBP1 |
Q5SRN2
|
testis expressed basic protein 1
|
|
1.5E-16 |
0.638 |
0.692 |
HLA-DQA1 |
P01909
|
major histocompatibility complex, class II, DQ alpha 1
|
Immune response
|
2.4E-02 |
0.416 |
0.846 |
HLA-DQA2 |
P01906
|
major histocompatibility complex, class II, DQ alpha 2
|
Immune response
|
1.0E-05 |
0.617 |
0.769 |
CLPTM1L |
Q96KA5
|
CLPTM1 like
|
Enzyme
|
4.4E-05 |
0.551 |
0.654 |
GGNBP1 |
Q5YKI7
|
gametogenetin binding protein 1 (pseudogene)
|
|
0.69 |
0.769 |
0.462 |
IRF4 |
Q15306
|
interferon regulatory factor 4
|
Transcription factor
|
0.86 |
0.491 |
0.769 |
MIR4435-2HG |
|
MIR4435-2 host gene
|
|
|
0.604 |
0.692 |
PCAT1 |
|
prostate cancer associated transcript 1
|
|
|
0.575 |
0.615 |
ACOXL |
Q9NUZ1
|
acyl-CoA oxidase like
|
Enzyme
|
5.2E-15 |
0.674 |
0.577 |
MYNN |
Q9NPC7
|
myoneurin
|
|
0.57 |
0.722 |
0.423 |
DRAIC |
|
downregulated RNA in cancer, inhibitor of cell invasion and migration
|
|
|
0.736 |
0.423 |
FARP2 |
O94887
|
FERM, ARH/RhoGEF and pleckstrin domain protein 2
|
|
4.6E-36 |
0.678 |
0.615 |
BAK1 |
Q16611
|
BCL2 antagonist/killer 1
|
Signaling
|
7.4E-06 |
0.555 |
0.769 |
BCL2 |
P10415
|
BCL2 apoptosis regulator
|
Signaling
|
0.56 |
0.291 |
0.885 |
SP140 |
Q13342
|
SP140 nuclear body protein
|
|
5.0E-08 |
0.691 |
0.577 |
PRKD2 |
Q9BZL6
|
protein kinase D2
|
Kinase
|
1.00 |
0.666 |
0.538 |
FAS |
P25445
|
Fas cell surface death receptor
|
|
0.81 |
0.372 |
0.923 |
GRAMD1B |
Q3KR37
|
GRAM domain containing 1B
|
|
1.00 |
0.736 |
0.385 |
CASC19 |
|
cancer susceptibility 19
|
|
|
0.769 |
0.423 |
IRF8 |
Q02556
|
interferon regulatory factor 8
|
Transcription factor
|
0.95 |
0.539 |
0.808 |
ACTA2 |
P62736
|
actin alpha 2, smooth muscle
|
Cellular structure
|
0.93 |
0.508 |
0.846 |
FKRP |
Q9H9S5
|
fukutin related protein
|
|
9.8E-06 |
0.513 |
0.731 |
CASP8 |
Q14790
|
caspase 8
|
Enzyme
|
3.7E-06 |
0.404 |
0.923 |
QPCT |
Q16769
|
glutaminyl-peptide cyclotransferase
|
Enzyme
|
1.2E-15 |
0.568 |
0.731 |